| abstract |
The present invention is dyslipidemia; High blood pressure; Type 2 diabetes mellitus, reduced glucose tolerance (IGT) or family history of diabetes; Hyperuricemia and / or gout; Coagulation state; Atherosclerosis; Or the use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the manufacture of a medicament for the treatment, alleviation, or prophylaxis of insulin resistance syndrome in which two or more of central obesity are present simultaneously in a subject, wherein the selective cGMP PDE5 inhibitor or Its pharmaceutical compositions can be used alone or in combination with other drugs to treat insulin resistance syndrome or individual aspects of insulin resistance syndrome. |